In 2018 was created Asabys Partners, which is appeared as VC. The fund was located in Europe if to be more exact in Spain. The leading representative office of defined VC is situated in the Barcelona.
Among the most popular portfolio startups of the fund, we may highlight Psious. For fund there is a match between the location of its establishment and the land of its numerous investments - Spain. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most successful fund investment fields, there are Wearables, Health Diagnostics.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Asabys Partners, startups are often financed by Atlantic Labs, Rothenberg Ventures, Founders Factory. The meaningful sponsors for the fund in investment in the same round are Sabadell Venture Capital, Ysios Capital, Omega Funds.
The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2019. Deals in the range of 5 - 10 millions dollars are the general things for fund. Considering the real fund results, this VC is 80 percentage points more often commits exit comparing to other organizations.
The current fund was established by Clara Campas, Josep L.l. Sanfeliu.
Related Funds
Fund Name | Location |
Business Investors Group (BiG) | Cheshire, Chester, United Kingdom |
Cornerstone Capital | Beijing, China, Haidian |
Crede CapitalGroup | California, Los Angeles, United States |
DCP Capital | Beijing, Beijing, China |
Dongxin Ziben | China, Jiangsu, Nanjing |
Florida Silicon Partners | Florida, Naples, United States |
G2 Momentum Capital | Distrito Federal, Mexico, Mexico City |
Grauer Brothers Capital | Atherton, California, United States |
INGENIUM Sardegna Fund | Belgium, Brussels, Brussels Hoofdstedelijk Gewest |
Intango Ventures | Israel, Tel Aviv, Tel Aviv District |
Inundata | New York, New York, United States |
Inventive Innovations | - |
Naspers Foundry | - |
New World Strategic Investment | China, Shanghai |
Simon Ventures | New York, New York, United States |
Sumitomo Mitsui Financial Group | Chiyoda, Japan |
Techstars Retail Accelerator | Minneapolis, Minnesota, United States |
W.IN.G | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Augustine Therapeutics | $20M | 26 Jun 2024 | Ghent, East Flanders, Belgium | ||
AgomAb Therapeutics | $111M | 11 Oct 2023 | Ghent, East Flanders, Belgium | ||
Gradient Denervation Technologies | $16M | 07 Sep 2023 | Paris, Ile-de-France, France | ||
Orikine Bio | $6M | 18 Jul 2023 | Barcelona, Catalonia, Spain | ||
Nuage Therapeutics | $14M | 14 Mar 2023 | Barcelona, Catalonia, Spain | ||
DeepUll | $20M | 01 Mar 2023 | Barcelona, Catalonia, Spain | ||
AgomAb Therapeutics | $45M | 13 Jul 2022 | Ghent, East Flanders, Belgium | ||
Psious | $8M | 28 Jun 2022 | Barcelona, Catalonia, Spain | ||
Cara Care | $7M | 13 Jun 2022 | Berlin, Berlin, Germany |
– INBRAIN Neuroelectronics S.L. announced $16.8m in Series A funding for its disruptive system for treating epilepsy and Parkinson’s disease.
– The investment was co-led by Asabys Partners and Alta Life Sciences and joined by Vsquared Ventures and TruVenturo GmbH.
– The funding will be used to advance INBRAIN’s first-in-human clinical program, aiming to establish the safety of graphene as the new standard of care for neurotechnology devices.
– INBRAIN’s technology harnesses the power of graphene, a two-dimensional material first isolated in 2004 made of a lattice of carbon atoms only one atom thick.
– MedLumics, a privately held medical device company developing AblaView®, the first optically-guided real-time ablation catheter system for the treatment of Atrial Fibrillation (AF), announced today that it has closed an upsized EUR 18 million (USD 21.7 million) financing round.
– MedLumics’ optical catheter displays lesion creation in real-time providing the physician with direct visual confirmation of conduction tissue denaturation.
– This round was led by Asabys Partners, along with new investors, VI Partners Swiss Innovation and CDTI Innvierte Economía, and existing investors Andera Partners, Caixa Capital Risc and Innogest Capital II.
– MedLumics is now ready to initiate first in-human regulatory clinical studies and automate scalable product manufacturing.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Augustine Therapeutics | $20M | 26 Jun 2024 | Ghent, East Flanders, Belgium | ||
AgomAb Therapeutics | $111M | 11 Oct 2023 | Ghent, East Flanders, Belgium | ||
Gradient Denervation Technologies | $16M | 07 Sep 2023 | Paris, Ile-de-France, France | ||
Orikine Bio | $6M | 18 Jul 2023 | Barcelona, Catalonia, Spain | ||
Nuage Therapeutics | $14M | 14 Mar 2023 | Barcelona, Catalonia, Spain | ||
DeepUll | $20M | 01 Mar 2023 | Barcelona, Catalonia, Spain | ||
AgomAb Therapeutics | $45M | 13 Jul 2022 | Ghent, East Flanders, Belgium | ||
Psious | $8M | 28 Jun 2022 | Barcelona, Catalonia, Spain | ||
Cara Care | $7M | 13 Jun 2022 | Berlin, Berlin, Germany |